| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
| Targets |
JC2-11 targets multiple inflammasome complexes. Inflammasomes are multi-protein complexes that play a critical role in the innate immune response by activating caspase-1, which leads to the processing and secretion of pro-inflammatory cytokines IL-1β and IL-18. JC2-11 inhibits the activation of the NLRP3, NLRC4, AIM2, and non-canonical inflammasomes. It exerts its effects by reducing mitochondrial reactive oxygen species (ROS) production, inhibiting caspase-1 activity, and lowering IL-1β secretion. This broad-spectrum activity makes it a valuable tool for studying inflammasome biology.
|
|---|---|
| ln Vitro |
In vitro, JC2-11 is a potent inhibitor of inflammasome activation. It inhibits the recruitment domain-containing proteins NLRC4, AIM2, and non-canonical (NC) inflammasomes. It reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the release of IL-1β and lactate dehydrogenase (LDH) from inflammasome-activated cells. By inhibiting ROS production and caspase-1 activity, it effectively blocks the inflammatory cascade downstream of inflammasome activation.
|
| ln Vivo |
JC2-11 (250 μg/mouse; intraperitoneal injection; single dosage) reduced NC Activation of the inflammasome and dramatically decreased the release of caspase-1 (p20) and IL-1β in the non-canonical (NC) inflammasome in the C57BL/6 mouse model [1].
In vivo, JC2-11 has demonstrated efficacy in a mouse model of inflammation. In C57BL/6 mice, a single intraperitoneal injection of JC2-11 (250 μg/mouse) reduced non-canonical (NC) inflammasome activation and dramatically decreased the release of caspase-1 (p20) and IL-1β. This confirms the compound's ability to inhibit inflammasome activation in a living organism and supports its use as a pharmacological tool for studying inflammasome-driven pathology. |
| Enzyme Assay |
The inhibitory activity of JC2-11 is typically assessed using in vitro inflammasome activation assays. Primary macrophages, such as bone marrow-derived macrophages (BMDMs), are primed with LPS and then stimulated with various inflammasome activators (e.g., nigericin for NLRP3, flagellin for NLRC4, poly(dA:dT) for AIM2). Cells are treated with varying concentrations of JC2-11, and the secretion of IL-1β and IL-18 is measured by ELISA. Caspase-1 activation is assessed by measuring the cleavage of its substrate or by Western blot for caspase-1 (p20). These assays quantify the compound's potency in inhibiting inflammasome activation.
|
| Cell Assay |
The cellular activity of JC2-11 is evaluated in immune cells, such as macrophages or dendritic cells. Cells are treated with JC2-11 and then stimulated with inflammasome activators. The production of IL-1β and IL-18 in the supernatant is measured by ELISA. The cleavage of gasdermin D (GSDMD) and caspase-1 is assessed by Western blot. The release of lactate dehydrogenase (LDH) is measured as an indicator of cell lysis. These assays confirm the compound's ability to inhibit inflammasome activation and pyroptosis.
|
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice (8 weeks, female)[1].
Doses: 250 μg/mouse. Route of Administration: intraperitoneal (ip)injection; single dose. Experimental Results: demonstrated inhibitory effect on NC inflammatory body. In animal studies, JC2-11 is typically administered to mice via intraperitoneal (i.p.) injection. In the cited study, a single dose of 250 μg/mouse was used. In models of inflammasome-driven diseases, such as sepsis, peritonitis, or inflammatory bowel disease, the compound could be given to assess its effect on disease severity and inflammatory markers. Efficacy endpoints include the measurement of IL-1β and IL-18 levels in serum or tissues, as well as histopathological analysis. |
| ADME/Pharmacokinetics |
JC2-11 is a small molecule with a molecular weight of 302.30 and a formula of C17H15FO4. It is soluble in DMSO (≥100 mg/mL) and is typically stored as a powder at -20°C or in solution at -80°C. Its chemical name is (E)-1-(3-fluoro-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one. Detailed pharmacokinetic parameters, such as half-life and bioavailability, are not extensively documented in publicly available sources.
|
| Toxicity/Toxicokinetics |
Toxicology data for JC2-11 is limited, as it is a research compound not intended for human therapeutic use. Its safety profile has not been established in formal toxicology studies. However, its use in animal models at the reported dose (250 μg/mouse) suggests it is tolerated in those contexts. Its use is limited to research applications and it is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
JC2-11 (CAS: 937820-89-8) is a valuable and widely used chemical probe for studying inflammasome biology. Its broad-spectrum activity against multiple inflammasome complexes (NLRP3, NLRC4, AIM2, non-canonical) makes it a key tool for dissecting the role of inflammasomes in various diseases. The compound's mechanism of action involves the inhibition of ROS production and caspase-1 activity. It was characterized in a study on benzylideneacetophenone derivatives that attenuate inflammasome activation. It is available from various commercial suppliers for research purposes.
|
| Molecular Formula |
C17H15FO4
|
|---|---|
| Molecular Weight |
302.297008752823
|
| Exact Mass |
302.095
|
| CAS # |
937820-89-8
|
| PubChem CID |
24895134
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
398
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=CC=C(OC)C(F)=C1)(=O)/C=C/C1=CC=C(O)C(OC)=C1
|
| InChi Key |
YYAIFDXWRNNHAW-ZZXKWVIFSA-N
|
| InChi Code |
InChI=1S/C17H15FO4/c1-21-16-8-5-12(10-13(16)18)14(19)6-3-11-4-7-15(20)17(9-11)22-2/h3-10,20H,1-2H3/b6-3+
|
| Chemical Name |
(E)-1-(3-fluoro-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
|
| Synonyms |
JC2-11; JC211; JC2 11
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~330.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3080 mL | 16.5399 mL | 33.0797 mL | |
| 5 mM | 0.6616 mL | 3.3080 mL | 6.6159 mL | |
| 10 mM | 0.3308 mL | 1.6540 mL | 3.3080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
